Corbus Pharmaceuticals Holdings Inc stock page - price, fundamentals, dividends - iOCharts

Ticker
CRBP

Price
0.35
Stock movement up
+0.02 (5.36%)
Company name
Corbus Pharmaceuticals Holdings Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
43.55M
Ent value
21.04M
Price/Sales
-
Price/Book
0.71
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-61.90%
1 year return
-79.55%
3 year return
-63.92%
5 year return
-44.33%
10 year return
-
Last updated: 2022-05-19

DIVIDENDS

CRBP does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book0.71
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count125.26M
EPS (TTM)-75358.98
FCF per share (TTM)-0.30

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)233.88K
Operating income (TTM)-49.09M
Net income (TTM)-9437.27B
EPS (TTM)-75.36K
EPS (1y forward)-0.30

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash57.03M
Net receivables0.00
Total current assets88.48M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets95.68M
Accounts payable2.70M
Short/Current long term debt26.17M
Total current liabilities15.12M
Total liabilities34.52M
Shareholder's equity61.16M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-36.99M
Capital expenditures (TTM)81.72K
Free cash flow (TTM)-37.07M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-214748.36%
Return on Assets-214748.36%
Return on Invested Capital-214748.36%
Cash Return on Invested Capital-45.39%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.33
Daily high0.36
Daily low0.33
Daily Volume1.30M
All-time high10.35
1y analyst estimate1.98
Beta1.90
EPS (TTM)-75358.98
Dividend per share-
Ex-div date-
Next earnings date10 Aug 2022

Downside potential

Loading...
Downside potential data
CRBPS&P500
Current price drop from All-time high-96.64%-18.47%
Highest price drop-97.97%-56.47%
Date of highest drop12 May 20229 Mar 2009
Avg drop from high-50.17%-11.34%
Avg time to new high105 days12 days
Max time to new high1303 days1805 days
COMPANY DETAILS
CRBP (Corbus Pharmaceuticals Holdings Inc) company logo
Marketcap
43.55M
Marketcap category
Small-cap
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Employees
41
Investor relations
SEC filings
CEO
Yuval Cohen
Country
USA
City
Norwood
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that new preclinical data for CRB-601 are being presented today in an oral presentati...
May 11, 2022
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
May 10, 2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.
May 10, 2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CRB-601 are being presented in a poster at the A...
April 8, 2022
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.
March 31, 2022
Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals are part of today's Screen of the Week blog.
March 18, 2022
Want to try an out-of-the-box approach? Tap five stocks including CRI, TH, IQ, BKE and CRBP with increasing P/E ratios.
March 17, 2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate i...
March 11, 2022
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -2.70% and 12.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto...
March 8, 2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the fourth quarter and year...
March 8, 2022
Next page